Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 17, 2018. The document serves as a transaction notification reporting insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively details specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume (Shares) | Transaction Type |
|---|---|---|---|---|
| April 12, 2018 | Ordinary Shares (25p) | £14.3999 | 10,879.142 | Dividend Re-investment |
Note: Total volume is the aggregate of 9 individual transactions listed in the filing.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine acquisitions of ordinary shares by executives following the re-investment of dividends paid on April 12, 2018.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a statutory disclosure of specific share transactions executed on the London Stock Exchange (XLON).
Investor Verification Checklist
- Verify the total number of shares acquired by PDMRs via dividend re-investment plans (DRIP) on April 12, 2018.
- Confirm the transaction price of £14.3999 per share against market data for the London Stock Exchange on the transaction date.
- Identify the specific executives involved: Ms E Walmsley (CEO), Mr R G Connor, Mr L Debruyne, Mr S Dingemans (CFO), Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Mrs K Thomson, and Mr N Hirons.
- Note that these transactions were automatic re-investments and not discretionary open-market purchases.